Pancreatic Adenocarcinoma
283
59
95
96
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
43 trials with published results (15%)
Research Maturity
96 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.0%
34 terminated out of 283 trials
73.8%
-12.7% vs benchmark
5%
14 trials in Phase 3/4
45%
43 of 96 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 96 completed trials
Clinical Trials (283)
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
TCR1188-ABC Cells in KRAS-mutated Cancers
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer